Neonatal and Obstetrical Outcomes of Pregnancies Complicated by Alloimmunization.


Journal

Pediatrics
ISSN: 1098-4275
Titre abrégé: Pediatrics
Pays: United States
ID NLM: 0376422

Informations de publication

Date de publication:
24 May 2024
Historique:
accepted: 25 01 2024
medline: 24 5 2024
pubmed: 24 5 2024
entrez: 24 5 2024
Statut: aheadofprint

Résumé

Despite advances in the prevention of rhesus (Rh)(D) alloimmunization, alloantibodies to Rh(D) and non-Rh(D) red blood cell antigens continue to be detected in ∼4% of US pregnancies and can result in hemolytic disease of the fetus and newborn (HDFN). Recent reports on HDFN lack granularity and are unable to provide antibody-specific outcomes. The objective of this study was to calculate the frequency of alloimmunization in our large hospital system and summarize the outcomes based on antibody specificity, titer, and other clinical factors. We identified all births in a 6-year period after a positive red blood cell antibody screen result during pregnancy and summarized their characteristics and outcomes. A total of 707 neonates were born after a positive maternal antibody screen result (3.0/1000 live births). In 31 (4%), the positive screen result was due to rhesus immune globulin alone. Of the 676 neonates exposed to alloantibodies, the direct antibody test (DAT) result was positive, showing antigen-positivity and evidence of HDFN in 37% of those tested. Neonatal disease was most severe with DAT-positive anti-Rh antibodies (c, C, D, e, E). All neonatal red blood cell transfusions (15) and exchange transfusions (6) were due to anti-Rh alloimmunization. No neonates born to mothers with anti-M, anti-S, anti-Duffy, anti-Kidd A, or anti-Lewis required NICU admission for hyperbilirubinemia or transfusion. Alloimmunization to Rh-group antibodies continues to cause a majority of the severe HDFN cases in our hospital system. In neonates born to alloimmunized mothers, a positive DAT result revealing antigen-positivity is the best predictor of anemia and hyperbilirubinemia.

Sections du résumé

BACKGROUND AND OBJECTIVES UNASSIGNED
Despite advances in the prevention of rhesus (Rh)(D) alloimmunization, alloantibodies to Rh(D) and non-Rh(D) red blood cell antigens continue to be detected in ∼4% of US pregnancies and can result in hemolytic disease of the fetus and newborn (HDFN). Recent reports on HDFN lack granularity and are unable to provide antibody-specific outcomes. The objective of this study was to calculate the frequency of alloimmunization in our large hospital system and summarize the outcomes based on antibody specificity, titer, and other clinical factors.
METHODS UNASSIGNED
We identified all births in a 6-year period after a positive red blood cell antibody screen result during pregnancy and summarized their characteristics and outcomes.
RESULTS UNASSIGNED
A total of 707 neonates were born after a positive maternal antibody screen result (3.0/1000 live births). In 31 (4%), the positive screen result was due to rhesus immune globulin alone. Of the 676 neonates exposed to alloantibodies, the direct antibody test (DAT) result was positive, showing antigen-positivity and evidence of HDFN in 37% of those tested. Neonatal disease was most severe with DAT-positive anti-Rh antibodies (c, C, D, e, E). All neonatal red blood cell transfusions (15) and exchange transfusions (6) were due to anti-Rh alloimmunization. No neonates born to mothers with anti-M, anti-S, anti-Duffy, anti-Kidd A, or anti-Lewis required NICU admission for hyperbilirubinemia or transfusion.
CONCLUSIONS UNASSIGNED
Alloimmunization to Rh-group antibodies continues to cause a majority of the severe HDFN cases in our hospital system. In neonates born to alloimmunized mothers, a positive DAT result revealing antigen-positivity is the best predictor of anemia and hyperbilirubinemia.

Identifiants

pubmed: 38784990
pii: 197355
doi: 10.1542/peds.2023-064604
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 by the American Academy of Pediatrics.

Déclaration de conflit d'intérêts

CONFLICT OF INTEREST DISCLOSURES: The authors have indicated they have no potential conflicts of interest to disclose.

Auteurs

Timothy M Bahr (TM)

Obstetric and Neonatal Operations.
Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah.

Sarah M Tweddell (SM)

Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah.

Jennifer M Zalla (JM)

Obstetric and Neonatal Operations.

Donna Dizon-Townson (D)

Maternal-Fetal Medicine, Intermountain Health, Salt Lake City, Utah.

Robin K Ohls (RK)

Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah.

Erick Henry (E)

Obstetric and Neonatal Operations.

Sarah J Ilstrup (SJ)

Intermountain Health Transfusion Services and Department of Pathology, Intermountain Medical Center, Murray, Utah.

Walter E Kelley (WE)

American National Red Cross, Salt Lake City, Utah; and.
Department of Pathology, University of Arizona College of Medicine, Tucson, Arizona.

Con Yee Ling (CY)

Obstetric and Neonatal Operations.
Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah.

Peter C Lindgren (PC)

Obstetric and Neonatal Operations.

Elizabeth A O'Brien (EA)

Obstetric and Neonatal Operations.
Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah.

Robert D Christensen (RD)

Obstetric and Neonatal Operations.
Division of Neonatology, Department of Pediatrics, University of Utah Health, Salt Lake City, Utah.

Classifications MeSH